Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds-Reference-Cited by-同舟云学术

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Published:2023-05-12 Issue:5 Volume:15 Page:1484
ISSN:1999-4923
Container-title:Pharmaceutics
language:en
Short-container-title:Pharmaceutics

Author:

Rafael Diana¹²³^ORCID,Guerrero Marcelo⁴⁵,Marican Adolfo⁴⁵⁶^ORCID,Arango Diego⁷⁸,Sarmento Bruno⁹^ORCID,Ferrer Roser¹⁰^ORCID,Durán-Lara Esteban F.⁴⁵^ORCID,Clark Simon J.¹¹¹²¹³^ORCID,Schwartz Simo¹¹⁰^ORCID

Affiliation:

1. Drug Delivery & Targeting, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain

2. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain

3. Functional Validation & Preclinical Research (FVPR), 20 ICTS Nanbiosis, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain

4. Bio & Nano Materials Lab, Drug Delivery and Controlled Release, Departamento de Microbiología, Facultad de Ciencias de la Salud, Universidad de Talca, Talca 3460000, Chile

5. Center for Nanomedicine, Diagnostic & Drug Development (ND3), Universidad de Talca, Talca 3460000, Chile

6. Instituto de Química de Recursos Naturales, Universidad de Talca, Talca 3460000, Chile

7. Group of Biomedical Research in Digestive Tract Tumors, Vall d’Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain

8. Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain

9. i3S-Instituto de Investigação e Inovação, Saúde Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal

10. Clinical Biochemistry Group, Vall d’Hebron Hospital, 08035 Barcelona, Spain

11. Department for Ophthalmology, University Eye Clinic, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany

12. Institute for Ophthalmic Research, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany

13. Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK

Abstract

Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

Funder

ANID FONDECYT Regular

Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain

Publisher

MDPI AG

Subject

Pharmaceutical Science

Link

https://www.mdpi.com/1999-4923/15/5/1484/pdf

Reference190 articles.

1. Blindness and Vision Impairment;Adelson;Lancet Glob. Health,2021

2. Risk factors for progression of age-related macular degeneration;Heesterbeek;Ophthalmic Physiol. Opt.,2020